|
Association between hormone replace therapy and intracranial meningioma in post-menopausal women |
|||
| Exposure* |
Cases n |
Controls n |
OR (95% CI)† |
|
|
|||
| Hormone replacement therapy (HRT) |
|||
| Never |
38 |
58 |
Referent |
| Past |
40 |
73 |
0.7 (0.4 – 1.3) |
| Current use on reference date |
23 |
41 |
1.0 (0.4 – 2.2) |
| Years of HRT use |
|||
| Never |
38 |
58 |
Referent |
| Up to 5 years |
28 |
43 |
0.9 (0.4 – 1.7) |
| More than 5 years |
32 |
65 |
0.9 (0.5 – 1.7) |
| First HRT exposure relative to reference date |
|||
| Never |
38 |
58 |
Referent |
| 1–9 years before |
30 |
44 |
0.9 (0.4 – 1.9) |
| 10 or more years before |
31 |
62 |
0.9 (0.5 – 1.6) |
| Type of HRT preparation |
|||
| None |
38 |
58 |
Referent |
| Estrogen |
33 |
66 |
0.9 (0.5 – 1.6) |
| Estrogen and Progestin |
24 |
33 |
1.3 (0.6 – 2.8) |
|
* Reported exposure before reference date, which for a case and her two matched controls was the date the case had surgery for her meningioma. † Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable conditional logistic regression including continuous age and three categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. None of the tests for linear trend was significant. | |||
Custer et al. BMC Cancer 2006 6:152 doi:10.1186/1471-2407-6-152 |
|||